To determine the expression patterns of the RBBP6 spliced variants during arsenic trioxide-mediated cell cycle arrest and curcumin-induced apoptosis in MCF-7 cells.
As 2O 3 and curcumin were used to study cytotoxicity, cell cycle arrest, apoptosis and the expression of RBBP6 variants. The MUSE Cell Analyser was used to analyze cell cycle arrest, apoptosis and multicaspase activity while apoptosis was further confirmed using microscopy. Semi-quantitative RT-PCR was employed to quantitate the expression of the RBBP6 variants.
This study showed that the MCF-7 cells expressed RBBP6 variant 1 but lacked both variant 2 and variant 3. Both As 2O 3 and curcumin significantly downregulated RBBP6 variant 1 (p < 0.001).
Understanding how breast cancer develops remains to be fully understood. It is known that genes play a pivotal role in the carcinogenesis process. The RBBP6 gene, which has different variants, has been reported to be involved in cancer development but it remains unclear which RBBP6 product is involved in cancer development. This study has demonstrated that there are RBBP6 variants that are pro-carcinogenic and those that are anti-carcinogenic. This study further showed that arsenic trioxide and curcumin lowered the expression of the RBBP6 splice variant 1 in MCF-7 breast cancer cells. Therefore, targeting RBBP6 variants for future drug development is a promising strategy.